Is Pfizer-Allergan the End of Tax Inversion Deals?
Pfizer Inc. and Allergan agreed to end their $160 billion merger agreement following U.S. government action on tax inversions. Bloomberg's Matt Campbell examines where the two companies go from here and how the end of the agreement may impact the future of corporate tax inversions. He speaks on "Bloomberg ‹GO›." (Source: Bloomberg)
Most Recent Videos
Grover Norquist on Tax Reform Under Trump
25:23 - Americans for Tax Reform president Grover Norquist discusses possible outcomes from Trump tax reform plan. He speaks with Bloomberg's David Westin on "Bloomberg Daybreak: Americas." (Source: Bloomberg)